Windlas Biotech Ltd Financials
Company Logo

Windlas Biotech Ltd Financial Statement

Windlas Biotech Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2025
Revenue215.33
Operating Expense183.57
Net Profit17.67
Net Profit Margin8.21
Earning Per Share8.43
EBIDTA31.73
Effective Tax Rate17.47

Windlas Biotech Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual759.88
Operating Expenses Annual665.76
Operating Profit Annual111.76
Interest Annual4.38
Depreciation26.88
Net Profit Annual60.65
Tax Annual18.75

Windlas Biotech Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning5.24
Cash Flow from Operations68.23
Cash Flow from Investing-74.06
Cash Flow from Financing1.01
Cash Flow at the End0.42

Windlas Biotech Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)14.71
PBIT Margin (%)11.02
PBT Margin (%)8.50
Net PROFIT Margin (%)7.98
Return On Networth / Equity (%)12.69
Return On Networth /Employed (%)16.79
Return On Assets (%)12.13
Total Debt / Equity (X)0.04
Asset Turnover Ratio (%)1.52

Windlas Biotech Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual225.51
Total Current Assets Annual525.13
Non Current Assets Annual235.32
Total Shareholders Funds Annual505.79
Total Assets Annual760.45

Windlas Biotech Ltd Earning Calls

EPS (INR)

Expected

8.43

Reported

8.43

Surprise

0.00%

Mar 2025

EPS beaten by 0.00%

Dec 2024

EPS beaten by 0.00%

Sep 2024

EPS beaten by 0.00%

FAQS on Windlas Biotech Ltd Financials

As of Aug 13, 2025, Windlas Biotech Ltd has a market capitalization of 2,176.14 Cr. Value Research classifies it as a Mid-Cap company.

Yes, Windlas Biotech Ltd is with a debt-to-equity ratio of 0.06.

In FY 2024 , Windlas Biotech Ltd recorded a total revenue of approximately 759.88 Cr marking a significant milestone in the company's financial performance.

Windlas Biotech Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.8% and 0.2% annually, respectively..

Windlas Biotech Ltd's current PE ratio is 35.88.

Windlas Biotech Ltd's ROCE averaged 15.6% from the FY ending March 2023 to 2025, with a median of 15.6%. It peaked at 17.2% in March 2024, reflecting strong capital efficiency over the period..

Windlas Biotech Ltd's latest EBIT is Rs. 83.77 Cr, surpassing the average EBIT of Rs. 73.25 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions